Effect of acute alcohol injection on plasma beta-endorphin levels in Warsaw high-preferring rats treated with acamprosate and naltrexone

Pharmacological Reports

Volumn 59, Issue SUPPL. 1, 2007, Pages 243-248

  Zalewska Kaszubska, Jadwiga ^a   Gorska, Dorota ^a   Dyr, Wanda ^b   Czarnecka, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Acamprosate; Alchol preferring rats; Beta endorphin; Ethanol; Naltrexone

Indexed keywords

ACAMPROSATE; ALCOHOL; BETA ENDORPHIN; METHYLCELLULOSE; NALTREXONE; SODIUM CHLORIDE;

ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; MONOTHERAPY; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; RELAPSE; WITHDRAWAL SYNDROME;

EID: 38049101236     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Aguirre JC, Del Arbol JL, Raya J, Ruiz-Requena ME, Rico Irles J: Plasma beta-endorphin levels in chronic alcoholics. Alcohol, 1990, 7, 409-412.
2. Angwin P, Barchas JD: Use of silicic acid extraction and reversed-phase columns for rapid purification prior to radiommionoassay. J Chromatogr, 1982, 231, 173-177.
3. Boeijinga PH, Parot P, Soufflet L, Landron F, Danel T, Gendre I, Muzet M et al.: Pharmacodynamic effects of acamprosate on markers of cerebral function in alcohol-dependent subjects administered as pretreatment and during alcohol abstinence. Neuropsychobiology, 2004, 50, 71-77.
4. Bouza C, Magro A, Munoz A, Amate JM: Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction, 2004, 99, 811-828.
5. Dai X, Thavundayil J, Gianoulakis C: Differences in the peripheral levels of beta-endorphin in response to alcohol and stress as a function of alcohol dependence and family history of alcoholism. Alcohol Clin Exp Res, 2005, 29, 1965-1975.
6. Deas D, May MP, Randall C, Johnson N, Anton R: Naltrexone treatment of adolescent alcoholics: an open-label pilot study. J Child Adolesc Psychopharmacol, 2005, 15, 723-728.
7. Di Chiara G: Alcohol and dopamine. Alcohol Health Res World, 1997, 21, 108-114.
8. Dyr W, Kostowski W: Animal model of ethanol abuse: rats selectively bred for high and low voluntary alcohol intake. Acta Pol Pharm, 2000. 57, Suppl. Drug Res, 90-92.
9. Dyr W, Kostowski W: Preliminary phenotypic characterization of the Warsaw High Preferring (WHP) and Warsaw Low Preferring (WLP) lines of rats selectively bred for high and low ethanol consumption. Pol J Pharmacol, 2004, 56, 359-365.
10. Grisel JE, Mogil JS, Grahame NJ, Rubinstein M, Belknap JK, Crabbe JC, Low MJ: Ethanol oral self administration is increased in mutant mice with decreased beta-endorphin expression. Brain Res, 1999, 835, 62-67.
11. Feeney GF, Connor JP, Young RM, Tucker J, McPherson A: Combined acamprosate an d naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centre's experience with pharmacotherapy. Alcohol Alcohol, 2006, 41, 321-327.
12. Froehlich JC: The neurobiology of ethanol-opioid inter-action in ethanol reinforcement. Alcohol Clin Exp Res, 1996, 20, 8 Suppl, 181A-186A.
13. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P et al.: Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism. Arch Gen Psychiatry, 2003, 60, 92-99.
14. Kiefer F, Jahn H, Otte C, Nakovics H. Wiedemann K: Effects of treatment with acamprosate on β-endorphin plasma concentration in humans with high alcohol preference. Neurosci Lett, 2006, 404, 103-106.
15. Kiefer F, Wiedemann K: Combined therapy: what does acamprosate and naltrexone combination tell us? Alcohol Alcohol, 2004, 39, 542-547.
16. Kiefer F, Wiedemann K: Neuroendocine pathways of addictive behaviour. Addict Biol. 2004, 9, 205-212.
17. Koob GF, Rassnick S, Heinrichs S, Weiss F: Alcohol, the reward system and dependence. EXS, 1994, 71, 103-114.
18. Koob GF, Roberts AJ, Schulteis G, Parsons LH, Heyser CJ, Hyytia P, Merlo-Pich E, Weiss F: Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp Res, 1998, 22, 3-9.
19. Kranzler HR, Van Kirk J: Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res, 2001, 25, 1335-1341
20. Marchesi C, Chiodera P, Ampollini P, Volpi R, Coiro V: Beta-endorphin, adrenocorticotropic hormone and cortisol sectretion in abstinent alcoholics. Psychiatry Res, 1997, 72, 187-194.
21. Mattson ME, Litten RZ: Combining treatments for alcoholism: why and how? J Stud Alcohol Suppl, 2005, 15, 8-16.
22. Middaugh LD, Lee AM, Bandy AL: Ethanol reinforcement in nondeprived mice: effects of abstinence and naltrexone. Alcohol Clin Exp Res, 2000, 24, 1172-1179.
23. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E: Naltrexone for alcohol dependence: a randomized controlled trial. Addiction, 2001, 96, 1565-1573.
24. Nava F, Premi S. Manzato E, Lucchini A: Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptions. J Psych Drugs, 2006, 38, 211-217.
25. Pietrzak B. Czarnecka E: Effect of the combined administration of ethanol and acamprosate on rabbit EEG. Pharmacol Rep, 2005, 57, 61-69.
26. Rezvani AH, Overstreet DH, Mason GA, Janowsky DS, Hamedi M, Clark Jr E, Yang Y: Combination pharmacotherapy: a mixture of small doses of naltrexone, fluoxetine, and a thyrothropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol-preferring rats. Alcohol Alcohol, 2000, 35, 76-83.
27. Rok-Bujko P, Dyr W, Kostowski W: Operant self-administration of ethanol in Warsaw high-preferring (WHP) and Warsaw low-preferring (WLP) lines of rats. Pharmacol Rep, 2006, 58, 931-935.
28. Scott LJ, Figgitt DP, Keam SJ, Waugh J: Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence. CNS Drugs, 2005, 19, 445-464.
29. Streeton C, Whelan G: Naltfexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol, 2001, 36, 544-552.
30. Stromberg MF: The effect of baclofen alone and in combination with naltrexene on ethanol consumption in the rat. Pharmacol Biochem Behav, 2004, 78, 743-750.
31. Tambour S, Quertemont E: Preclinical and clinical pharmacology of alcohol dependence. Fundam Clin Pharmacol, 2007, 21, 9-28.
32. Van Ree JM: Endorphins and experimental addiction. Alcohol, 1996, 13, 25-30.
33. Van Ree JM, Kornet M, Goosen C: Neoropeptides and alcohol addiction in monkeys. EXS, 1994, 71, 165-174.
34. Verheul R, Lehert P, Geerlings PJ, Koster MW, van den Brink W: Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl), 2005, 178, 167-173.
35. Weinstein A, Feldtkeller B, Feeney A, Lingford-Hughes A, Nutt D: A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients. Addict Biol, 2003, 8, 229-232.
36. Zalewska-Kaszubska J, Obzejta D: Use of low-energy laser as adjunct treatment of alcohol addiction. Lasers Med Sci, 2004, 19, 100-104.
37. Zalewska-Kaszubska J, Czarnccka E: Deficit in beta-endorphin peptide and tendency to alcohol abuse. Peptides, 2005, 26, 701-705.
38. Zalewska-Kaszubska J, Cwiek W, Dyr W, Czarnecka E: Changes in the beta endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference. Neurosci Lett, 2005, 388, 45-48.
39. Zalewska-Kaszubska J, Górska D, Dyr W, Czarnecka E: Effect of acute administration of ethanol on beta-endorphin plasma level in ethanol preferring and non-preferring rats chronically treated with naltrexone. Pharmacol Biochem Behav, 2006, 85, 155-159.